Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

An exploratory genome-wide analysis of genetic risk for alcoholic hepatitis.

Beaudoin JJ, Long N, Liangpunsakul S, Puri P, Kamath PS, Shah V, Sanyal AJ, Crabb DW, Chalasani NP, Urban TJ; TREAT Consortium.

Scand J Gastroenterol. 2017 Nov;52(11):1263-1269. doi: 10.1080/00365521.2017.1359664. Epub 2017 Aug 4.

2.

Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.

Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, Aithal GP, Dillon J, Navarro V, Odin J, Barnhart H, Ostrov D, Long N, Cirulli ET, Watkins PB, Fontana RJ; Drug-Induced Liver Injury Network (DILIN); Pharmacogenetics of Drug-Induced Liver Injury group (DILIGEN); International Serious Adverse Events Consortium (iSAEC).

J Hepatol. 2017 Jul;67(1):137-144. doi: 10.1016/j.jhep.2017.03.010. Epub 2017 Mar 18.

3.

An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis.

Petrovski S, Todd JL, Durheim MT, Wang Q, Chien JW, Kelly FL, Frankel C, Mebane CM, Ren Z, Bridgers J, Urban TJ, Malone CD, Finlen Copeland A, Brinkley C, Allen AS, O'Riordan T, McHutchison JG, Palmer SM, Goldstein DB.

Am J Respir Crit Care Med. 2017 Jul 1;196(1):82-93. doi: 10.1164/rccm.201610-2088OC.

4.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

5.

Peptidomimetic therapeutics: scientific approaches and opportunities.

Qvit N, Rubin SJS, Urban TJ, Mochly-Rosen D, Gross ER.

Drug Discov Today. 2017 Feb;22(2):454-462. doi: 10.1016/j.drudis.2016.11.003. Epub 2016 Nov 14. Review.

6.

Transient Receptor Potential Vanilloid 1 Regulates Mitochondrial Membrane Potential and Myocardial Reperfusion Injury.

Hurt CM, Lu Y, Stary CM, Piplani H, Small BA, Urban TJ, Qvit N, Gross GJ, Mochly-Rosen D, Gross ER.

J Am Heart Assoc. 2016 Sep 26;5(9). pii: e003774.

7.

Reply.

De Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH.

Clin Gastroenterol Hepatol. 2016 Dec;14(12):1845-1846. doi: 10.1016/j.cgh.2016.08.011. Epub 2016 Aug 19. No abstract available.

PMID:
27546581
8.

Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.

Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ.

J Clin Pharmacol. 2017 Jan;57(1):118-124. doi: 10.1002/jcph.783. Epub 2016 Aug 4.

PMID:
27349952
9.

Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury.

de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH; Drug-Induced Liver Injury Network.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):103-112.e2. doi: 10.1016/j.cgh.2016.05.043. Epub 2016 Jun 14.

10.

HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.

Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium.

Pharmacogenet Genomics. 2016 May;26(5):218-24. doi: 10.1097/FPC.0000000000000209.

PMID:
26959717
11.

IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance.

Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS.

Sci Rep. 2015 Nov 4;5:16037. doi: 10.1038/srep16037.

12.

Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury.

Usachov V, Urban TJ, Fontana RJ, Gross A, Iyer S, Omary MB, Strnad P; Drug-Induced Liver Injury Network.

BMC Med. 2015 Aug 19;13:196. doi: 10.1186/s12916-015-0418-0.

13.

Clinical application of whole-genome sequencing in patients with primary immunodeficiency.

Mousallem T, Urban TJ, McSweeney KM, Kleinstein SE, Zhu M, Adeli M, Parrott RE, Roberts JL, Krueger B, Buckley RH, Goldstein DB.

J Allergy Clin Immunol. 2015 Aug;136(2):476-9.e6. doi: 10.1016/j.jaci.2015.02.040. Epub 2015 May 14. No abstract available.

14.

Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors.

Welch MA, Köck K, Urban TJ, Brouwer KL, Swaan PW.

Drug Metab Dispos. 2015 May;43(5):725-34. doi: 10.1124/dmd.114.062539. Epub 2015 Mar 3.

15.

Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2179-88. doi: 10.1128/AAC.04618-14. Epub 2015 Feb 2.

16.

Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.

Lu YF, Goldstein DB, Urban TJ, Bradrick SS.

Virology. 2015 Feb;476:334-340. doi: 10.1016/j.virol.2014.12.020. Epub 2015 Jan 9.

17.

Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice.

Church RJ, Gatti DM, Urban TJ, Long N, Yang X, Shi Q, Eaddy JS, Mosedale M, Ballard S, Churchill GA, Navarro V, Watkins PB, Threadgill DW, Harrill AH.

Food Chem Toxicol. 2015 Feb;76:19-26. doi: 10.1016/j.fct.2014.11.008. Epub 2014 Nov 28.

18.

A nonsense mutation in IKBKB causes combined immunodeficiency.

Mousallem T, Yang J, Urban TJ, Wang H, Adeli M, Parrott RE, Roberts JL, Goldstein DB, Buckley RH, Zhong XP.

Blood. 2014 Sep 25;124(13):2046-50. doi: 10.1182/blood-2014-04-571265. Epub 2014 Aug 18.

19.

Genetic basis of drug-induced liver injury: present and future.

Urban TJ, Daly AK, Aithal GP.

Semin Liver Dis. 2014 May;34(2):123-33. doi: 10.1055/s-0034-1375954. Epub 2014 May 31. Review.

PMID:
24879978
20.

Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.

Nelson D, Yoshida EM, Paulson MS, Hengen PN, Ge D, Kanwar B, McNally J, Pang PS, Subramanian GM, McHutchison JG, Urbanek P, Lawitz E, Urban TJ.

Antivir Ther. 2014;19(7):679-86. doi: 10.3851/IMP2747. Epub 2014 Feb 6.

PMID:
24503447
21.

Pharmacogenetics at 50: genomic personalization comes of age.

Urban TJ, Goldstein DB.

Sci Transl Med. 2014 Jan 22;6(220):220ps1. doi: 10.1126/scitranslmed.3005237.

PMID:
24452261
22.

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D'Ambrosio R, Muir AJ, Colombo M.

J Viral Hepat. 2013 Dec;20(12):858-66. doi: 10.1111/jvh.12113. Epub 2013 Jun 24.

PMID:
24304455
23.

Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.

Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL.

Drug Metab Dispos. 2014 Apr;42(4):665-74. doi: 10.1124/dmd.113.054304. Epub 2013 Oct 23.

24.

Nociceptive-induced myocardial remote conditioning is mediated by neuronal gamma protein kinase C.

Gross ER, Hsu AK, Urban TJ, Mochly-Rosen D, Gross GJ.

Basic Res Cardiol. 2013 Sep;108(5):381. doi: 10.1007/s00395-013-0381-x. Epub 2013 Aug 28.

25.

Understanding human variation in infectious disease susceptibility through clinical and cellular GWAS.

Ko DC, Urban TJ.

PLoS Pathog. 2013;9(8):e1003424. doi: 10.1371/journal.ppat.1003424. Epub 2013 Aug 1. Review. No abstract available.

26.

Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus.

Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, Chusri P, Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT.

Hepatology. 2014 Apr;59(4):1250-61. doi: 10.1002/hep.26653. Epub 2014 Feb 14.

27.

Whole-genome sequencing in pharmacogenetics.

Urban TJ.

Pharmacogenomics. 2013 Mar;14(4):345-8. doi: 10.2217/pgs.12.211. No abstract available.

PMID:
23438878
28.

Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes.

Wei R, Yang F, Urban TJ, Li L, Chalasani N, Flockhart DA, Liu W.

Front Genet. 2012 Nov 21;3:248. doi: 10.3389/fgene.2012.00248. eCollection 2012.

29.

Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.

Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB; Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium.

Pharmacogenet Genomics. 2012 Nov;22(11):784-95. doi: 10.1097/FPC.0b013e3283589a76.

30.

Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium.

Zhu Q, Ge D, Heinzen EL, Dickson SP, Urban TJ, Zhu M, Maia JM, He M, Zhao Q, Shianna KV, Goldstein DB.

Am J Hum Genet. 2012 Sep 7;91(3):422-34. doi: 10.1016/j.ajhg.2012.07.010. Epub 2012 Aug 30.

31.

Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?

Urban TJ, Goldstein DB, Watkins PB.

Pharmacogenomics. 2012 May;13(7):735-8. doi: 10.2217/pgs.12.45. No abstract available.

32.

The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.

Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL, Urban TJ, Shianna K, Fellay J, Goodman Z, Noviello S, Pedicone LD, Afdhal N, Sulkowski M, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ.

Dig Dis Sci. 2012 Aug;57(8):2213-21. doi: 10.1007/s10620-012-2171-y. Epub 2012 Apr 29. Erratum in: Dig Dis Sci. 2012 Sep;57(9):2479.

33.

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.

Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, Patel K, Harrison SA, Urban TJ, Naggie S, Fellay J, Tillmann HL, Shianna K, Noviello S, Pedicone LD, Esteban R, Kwo P, Sulkowski MS, Afdhal N, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ; IDEAL investigators.

J Viral Hepat. 2012 May;19(5):332-40. doi: 10.1111/j.1365-2893.2011.01553.x. Epub 2012 Feb 22.

34.

Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.

McCormack M, Urban TJ, Shianna KV, Walley N, Pandolfo M, Depondt C, Chaila E, O'Conner GD, Kasperavičiūtė D, Radtke RA, Heinzen EL, Sisodiya SM, Delanty N, Cavalleri GL.

Pharmacogenomics. 2012 Mar;13(4):399-405. doi: 10.2217/pgs.11.165.

35.

Copy number variation of KIR genes influences HIV-1 control.

Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, Ge D, De Luca A, Martinez-Picado J, Wolinsky SM, Martinson JJ, Jamieson BD, Bream JH, Martin MP, Borrow P, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Carrington M, Goldstein DB, Alter G; NIAID Center for HIV/AIDS Vaccine Immunology.

PLoS Biol. 2011 Nov;9(11):e1001208. doi: 10.1371/journal.pbio.1001208. Epub 2011 Nov 29. Erratum in: PLoS Biol. 2011 Dec;9(12). doi:10.1371/annotation/7e17b146-a69c-4e83-9230-7340486d9dc8.

36.

Genetic and environmental correlates of topiramate-induced cognitive impairment.

Cirulli ET, Urban TJ, Marino SE, Linney KN, Birnbaum AK, Depondt C, Attix DK, Radtke RA, Goldstein DB.

Epilepsia. 2012 Jan;53(1):e5-8. doi: 10.1111/j.1528-1167.2011.03322.x. Epub 2011 Nov 16.

37.

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL, Naggie S, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, King JW, Kwo PY, Shianna KV, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Goldstein DB, McHutchison JG, Muir AJ.

J Hepatol. 2012 Feb;56(2):313-9. doi: 10.1016/j.jhep.2011.04.021. Epub 2011 May 20.

38.

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC.

Gastroenterology. 2011 Jul;141(1):338-47. doi: 10.1053/j.gastro.2011.04.001. Epub 2011 Apr 12.

39.

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ, Goldstein DB.

Gastroenterology. 2011 Apr;140(4):1314-21. doi: 10.1053/j.gastro.2010.12.038. Epub 2011 Jan 1.

PMID:
21199653
40.

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N.

Hepatology. 2010 Dec;52(6):1888-96. doi: 10.1002/hep.23912. Epub 2010 Oct 7.

41.

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Oct;139(4):1181-9. doi: 10.1053/j.gastro.2010.06.016. Epub 2010 Jun 12.

42.

Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes.

Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, Walley NM, Nicoletti P, Ge D, Catarino CB, Duncan JS, Kasperaviciūte D, Tate SK, Caboclo LO, Sander JW, Clayton L, Linney KN, Shianna KV, Gumbs CE, Smith J, Cronin KD, Maia JM, Doherty CP, Pandolfo M, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Kälviäinen R, Eriksson K, Kantanen AM, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Wieser HG, Zumsteg D, Ortega M, Wood NW, Huxley-Jones J, Mikati M, Gallentine WB, Husain AM, Buckley PG, Stallings RL, Podgoreanu MV, Delanty N, Sisodiya SM, Goldstein DB.

Am J Hum Genet. 2010 May 14;86(5):707-18. doi: 10.1016/j.ajhg.2010.03.018. Epub 2010 Apr 15.

43.

Race, ethnicity, ancestry, and pharmacogenetics.

Urban TJ.

Mt Sinai J Med. 2010 Mar-Apr;77(2):133-9. doi: 10.1002/msj.20168. Review.

PMID:
20309922
44.

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB.

Nature. 2010 Mar 18;464(7287):405-8. doi: 10.1038/nature08825. Epub 2010 Feb 21.

PMID:
20173735
45.

Common genetic variation and the control of HIV-1 in humans.

Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

PLoS Genet. 2009 Dec;5(12):e1000791. doi: 10.1371/journal.pgen.1000791. Epub 2009 Dec 24.

46.

CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Chaudhry AS, Urban TJ, Lamba JK, Birnbaum AK, Remmel RP, Subramanian M, Strom S, You JH, Kasperaviciute D, Catarino CB, Radtke RA, Sisodiya SM, Goldstein DB, Schuetz EG.

J Pharmacol Exp Ther. 2010 Feb;332(2):599-611. doi: 10.1124/jpet.109.161026. Epub 2009 Oct 23.

47.

CCL3L1 and HIV/AIDS susceptibility.

Urban TJ, Weintrob AC, Fellay J, Colombo S, Shianna KV, Gumbs C, Rotger M, Pelak K, Dang KK, Detels R, Martinson JJ, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Telenti A, Michael NL, Goldstein DB.

Nat Med. 2009 Oct;15(10):1110-2. doi: 10.1038/nm1009-1110. No abstract available.

48.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB.

Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16.

PMID:
19684573
49.

The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel.

McBride BF, Yang T, Liu K, Urban TJ, Giacomini KM, Kim RB, Roden DM.

J Cardiovasc Pharmacol. 2009 Jul;54(1):63-71. doi: 10.1097/FJC.0b013e3181abc288.

50.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.

Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM.

Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.

Supplemental Content

Loading ...
Support Center